[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"camrelizumab\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:camrelizumab":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,44,76,106,132],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100553390","phase-3-tace-plus-camrelizumab-and-apatinib-for-unresectable-hepatocellular-carcinoma-100553390",false,"NCT06485466","TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma","Transarterial Chemoembolization Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma : a Randomised , Open Label, Multicenter Controlled Trial","Inclusion Criteria:\n\n1. Histopathologically or clinically confirmed hepatocellular carcinoma\n2. 18-80 years old.\n3. Performance status (PS) ≤ 1 (ECOG scale).\n4. Barcelona clinical liver cancer (BCLC) stage B or stage C.\n5. Initial treatment of hepatocellular carcinoma.\n6. According to mRECIST, there is at least one measurable lesion.\n7. Child Pugh score ≤ 7.\n8. Participant has sufficient organ and marrow functions.\n9. Expected survival time ≥ 12 weeks.\n10. For women of childbearing age or male patients whose sexual partners are women of childbearing age, effective contraceptive measures should be taken during the whole treatment period and 6 months after the last medication.\n11. Sign the written informed consent, and be able to follow the visit and relevant procedures specified in the plan.\n\nExclusion Criteria:\n\n1. Fibrolamellar carcinoma, sarcomatoid carcinoma, cholangiocarcinoma and other components previously confirmed by histology \u002F cytology.\n2. History of hepatic encephalopathy or liver transplantation.\n3. Pleural effusion, ascites and pericardial effusion with clinical symptoms requiring drainage.\n4. Tumor burden≥70%, diffuse liver cancer or tumor is not suitable for mRECIST standard evaluation.\n5. Received local treatment (ablation therapy, TACE), surgery resection and radiotherapy for liver cancer before the first administration.\n6. Have received systemic chemotherapy, targeted therapy or immunotherapy\n7. There is a significant decrease in white blood cells and platelets in peripheral blood, severe coagulation dysfunction and can not be corrected：the neutrophil\\\u003C1.5×109\u002FL, PLT\\\u003C50×109\u002FL. The INR\\>2.3\n8. Acute or chronic active hepatitis B or C infection, hepatitis B virus (HBV-DNA) \\> 10\\^6 copies \u002F ml; hepatitis C virus (HCV-RNA) \\> 10\\^3 copies \u002F ml; HBsAg and anti HCV antibody were positive at the same time.\n9. There is central nervous system metastasis.\n10. Bleeding of esophageal or gastric varices caused by portal hypertension occurred in the past 6 months, or severe (G3) varices were found in endoscopic examination within 3 months before the first administration, or evidence of portal hypertension (including splenomegaly found in imaging examination) was found. The researchers assessed that the risk of bleeding was high and did not receive sclerotherapy or ligation under the endoscope.\n11. The previous 6-month history of arteriovenous thromboembolism, including myocardial infarction, unstable angina, cerebrovascular accident, pulmonary embolism, deep vein thrombosis or any other serious thromboembolism. The thrombus of implanted vein port or catheter source or superficial vein is stable after routine anticoagulant treatment. Prophylactic use of low-molecular-weight heparin (e.g., enoxaparin 40 mg \u002F day) is permitted.\n12. Tumor thrombus of main portal vein, or involving superior mesenteric vein at the same time.\n13. Aspirin (\\> 325 mg \u002F day) or other drugs known to inhibit platelet function such as dipyridamole or clopidogrel were used for 7 consecutive days within 2 weeks before the first administration.\n14. For uncontrolled hypertension, systolic blood pressure \\> 150 mmHg or diastolic blood pressure \\> 100 mmHg after the best medical treatment, hypertension crisis or hypertension encephalopathy history.\n15. Symptomatic congestive heart failure (New York Heart Association class II-IV). Symptomatic or poorly controlled arrhythmias. The corrected QT interval (QTc) for the history or screening of congenital long QT syndrome was more than 500 ms (calculated by Fridericia method).\n16. Serious bleeding tendency or coagulation dysfunction, or undergoing thrombolysis.\n17. In the past 6 months, there was a history of gastrointestinal perforation and \u002F or fistula, a history of intestinal obstruction (including incomplete intestinal obstruction requiring parenteral nutrition), extensive enterotomy (partial colectomy or extensive enterotomy with chronic diarrhea), Crohn's disease, ulcerative colitis or long-term chronic diarrhea.\n18. Previous and current pulmonary fibrosis history, interstitial pneumonia, pneumoconiosis, drug-related pneumonia, severe impairment of lung function and other lung diseases.\n19. Active tuberculosis (TB), who is receiving anti TB treatment or has received anti TB treatment within one year before the first administration.\n20. People with HIV infection (HIV 1 \u002F 2 antibody positive) and known syphilis infection. Serious infection in active stage or poor clinical control.\n21. Severe infection within 4 weeks before the first administration, including but not limited to hospitalization due to complications of infection, bacteremia or severe pneumonia.\n22. Active autoimmune diseases requiring systemic treatment (such as the use of disease alleviation drugs, corticosteroids or immunosuppressants) occurred within 2 years before the first administration. Alternative therapies (e.g. thyroxine, insulin, or physiological corticosteroids for adrenal or pituitary insufficiency) are permitted. Known history of primary immunodeficiency. Only the patients with positive autoimmune antibody need to confirm whether there is autoimmune disease according to the judgment of researchers.\n23. Immunosuppressive drugs were used within 4 weeks before the first administration, excluding local glucocorticoids or systemic glucocorticoids (i.e.\n\n    no more than 10 Mg \u002F day prednisone or the equivalent dose of other glucocorticoids), allowing temporary use of glucocorticoids due to dyspnea symptoms in the treatment of asthma, chronic obstructive pulmonary disease and other diseases.\n24. Receive live attenuated vaccine within 4 weeks before the first administration or during the study period.\n25. Major surgical procedures (craniotomy, thoracotomy or open hand) were performed within 4 weeks before the first administration (surgery) or an unhealed wound, ulcer, or fracture.\n26. Uncontrolled \u002F uncorrectable metabolic disorder or other non- malignant organ disease or systemic disease or cancer secondary reaction, which may lead to higher medical risk and \u002F or uncertainty of survival evaluation.\n27. Known to be allergic to any PD-1 monoclonal antibody component.\n28. Women of childbearing age who are unwilling or unable to use acceptable methods of contraception during the whole treatment period of this trial and within 12 weeks after the last administration of the study drug (women of childbearing age include: any women who have had menarche, and have not undergone successful artificial sterilization (hysterectomy, bilateral tubal ligation, or bilateral ovariectomy), pregnancy or lactation Women; women with positive pregnancy test results at the time of inclusion or before study drug administration; If the partner is a woman of childbearing age, the subject is a fertile male without effective contraceptive measures.","ALL","18 Years","80 Years",{"count":20,"type":21},101,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third most common cause of cancer-related death worldwide. The majority of patients with HCC are diagnosed as intermediate or advanced stage disease, and not eligible for curative treatments including transplantation, resection, and ablation. Transarterial chemoembolization (TACE) is recommended as first-line treatment for patients with intermediate-stage HCC, while it is also widely used in the unresectable HCC.\n\nThe clinical efficacy and safety in advanced HCC patients of camrelizumab plus apatinib were reported in phase 3 trial (CARES-310). Camrelizumab plus apatinib with a median progression-free survival of 5.7 months and a median overall survival of 22.1 months in advanced HCC.\n\nThis study is randomized, open-label, multicenter controlled trial; which was focused in initial BCLC-B\u002FC HCC patients. This study aimed to compare the efficacy and safety of TACE plus programmed death-1 inhibitor (camrelizumab), and anti-angiogenic therapy (apatinib) with camrelizumab plus apatinib.",[27,28,29,30],"Unresectable Hepatocellular Carcinoma","Transarterial Chemoembolization","Camrelizumab","Apatinib","RECRUITING","2026-04-12",{"date":34,"type":35},"2026-04-14","ACTUAL",{"date":37,"type":35},"2024-08-10",{"date":39,"type":21},"2028-06-30",{"name":41,"class":42},"Guohui Xu","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":63,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":43},"100478631","phase-2-camrelizumab-plus-apatinib-and-temozolomide-as-neoadjuvant-in-high-risk-acral-melanoma-100478631","NCT05512481","Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma","A Phase 2 Clinical Trial of Neoadjuvant Camrelizumab Plus Apatinib and Temozolomide in High Risk Clinical Stage Ⅱ-Ⅲ Acral Melanoma","Inclusion Criteria:\n\n1. age:18-75 years, male or female.\n2. Histopathologically confirmed acral melanoma (stage Ⅱ\u002FⅢ).\n3. Has not received any systematic anti-tumor drug treatment.\n4. Measurable disease based on Response Evaluation Criteria In Solid Tumors (RECIST) 1.1.\n5. ECOG 0-1.\n6. Adequate organ function.\n7. Life expectancy of greater than 12 weeks.\n8. Patient has given written informed consent.\n\nExclusion Criteria:\n\n1. Patients who have or are currently undergoing additional chemotherapy, radiation therapy, targeted therapy or immunotherapy.\n2. Known history of hypersensitivity to any component of apatinib, temozolomide, Camrelizumab.\n3. Subjects before or at the same time with other malignant tumors (except which has cured skin basal cell carcinoma and cervical carcinoma in situ);\n4. Subjects with any active autoimmune disease or history of autoimmune disease\n5. Patients with any unstable systemic disease, including but not limited to: serious infection, uncontrolled diabetes, unstable angina pectoris, cerebrovascular accident or transient ischemic attack, myocardial infarction, congestive heart failure, serious cardiac arrhythmia requiring medication, hepatic, renal or metabolic disease;\n6. Received a live vaccine within 4 weeks of the first dose of study medication.\n7. Pregnancy or breast feeding.\n8. Decision of unsuitableness by principal investigator or physician-in charge.","75 Years",{"count":53,"type":21},60,[55],"PHASE2","Neoadjuvant therapy is feasible in stage Ⅱ-Ⅲ melanoma, Carrelizumab combined with apatinib and temozolomide has synergistic antitumor effects and may improve pathological response.",[58,59,60,30,29,61,62],"Melanoma","Acral Melanoma","Temozolomide","Neoadjuvant","Pathological Response",[59,64,65,66],"Immune Checkpoint Inhibitors","Protein Kinase Inhibitors","Antineoplastic Agents, Alkylating","2025-02-28",{"date":69,"type":35},"2025-03-03",{"date":71,"type":35},"2022-09-13",{"date":73,"type":21},"2026-12-31",{"name":75,"class":42},"Peking University Cancer Hospital & Institute",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":83,"minAge":17,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":88,"conditions":89,"keywords":92,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":43},"100475803","phase-2-clinical-study-of-camrelizumab-combined-with-tcb-versus-tcb-in-neoadjuvant-treatment-of-triple-negative-breast-cancer-100475803","NCT05475678","Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer","A Randomized, Open Label, Parallel Controlled, Multicenter Phase II Clinical Study of Carelizumab Combined With TCb (Docetaxel+Carboplatin) Versus TCb Neoadjuvant Therapy for Triple Negative Breast Cancer","Inclusion Criteria:\n\n1. Age: 18-70 years old\n2. cT2 - cT4d, or cT1c with axillary lymph node metastasis confirmed clinically and pathologically；\n3. Pathologically proven triple negative breast cancer:\n\n   Triple-negative breast cancer is defined as:\n   * Negative for ER and PR (IHC nuclear staining \\\u003C10%)\n   * Her-2 negative (IHC 0, 1+ without FISH, or IHC 2+ with no amplification by FISH)；\n4. Has clinically measurable lesions:Measurable lesions on ultrasound, mammography, or MR (optional) within 1 month before randomization；\n5. Organ and bone marrow function tests within 1 month before chemotherapy suggest no contraindications to chemotherapy；\n6. Cardiac ultrasound EF value ≧55%；\n7. Females of childbearing age, with a negative serum pregnancy test 14 days before randomization;\n8. ECOG score≤1 point;\n9. Sign informed consent；\n\nExclusion Criteria:\n\n1. The patient has evidence of metastatic breast cancer；\n2. For this disease, chemotherapy, endocrine therapy, targeted therapy, radiation therapy, etc. have been received;\n3. The patient has a second primary malignancy other than adequately treated skin cancer;\n4. The patient has been treated with anti-programmed cell death protein 1 (anti-PD-1), anti-programmed death ligand 1 (anti-PD-L1) or anti-PD-L2 drugs, or other immunotherapy；\n5. The patient has been diagnosed with immunodeficiency disease or autoimmune disease;\n6. The patient has severe lung or heart disease;\n7. The patient has active hepatitis B and C;\n8. The patient has a history of organ transplantation or bone marrow transplantation;\n9. pregnant or breastfeeding women;\n10. The investigators considered chemotherapy contraindicated due to serious, uncontrolled other medical conditions.","FEMALE","70 Years",{"count":86,"type":21},369,[55],"Triple-negative breast cancer (TNBC) is a special subtype of breast cancer that lacks the expression of ER, PR, and Her-2 proteins, accounting for 15%-20% of all breast cancers.TNBC patients do not benefit from endocrine therapy or HER-2-targeted therapy, but are sensitive to cytotoxic drug therapy.Although the survival of TNBC patients has improved significantly compared with the past, it is still the type with the worst prognosis among all subtypes of breast cancer. Methods and drugs to further improve the therapeutic effect of TNBC patients are still being explored.\n\nCamrelizumab, a PD-1 inhibitor produced by Hengrui, has been approved for the treatment of various malignant tumors including advanced lung cancer, advanced liver cancer and advanced esophageal cancer. Shows good therapeutic effect and safety.\n\nTherefore, this study intends to explore the superiority of camrelizumab on the basis of the less toxic anthracycline-free TCb regimen.In order to provide more effective and safe neoadjuvant therapy for lymph node-positive TNBC patients.",[90,91,29],"Breast Cancer","Triple Negative Breast Cancer",[91,29,93,94,95],"Neoadjuvant chemotherapy","Pathological complete response rate","Disease-free survival","2025-01-21",{"date":98,"type":35},"2025-01-23",{"date":100,"type":35},"2022-12-20",{"date":102,"type":21},"2029-12-31",{"name":104,"class":105},"Zhenzhen Liu","OTHER_GOV",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":113,"targetDuration":4,"studyType":22,"phases":115,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":43},"100520800","btae-haic-combined-with-system-therapy-for-intermediate-advanced-huge-hcc-100520800","NCT06061276","bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC","Sequential bTAE-HAIC Combined With Lenvatinib and Camrelizumab for Intermediate-advanced Huge Hepatocellular Carcinoma","Inclusion Criteria:\n\n1. Clinical diagnosis of HCC.\n2. Age between 18 and 75 years;\n3. The maximum tumor size ≥10 cm, and the total tumor size ≥15 cm;\n4. Intermediate-advanced huge HCC, advanced HCC with PVTT type I or type II or limited metastases (≤5).\n5. Child-Pugh class A or B;\n6. Eastern Cooperative Group performance status (ECOG) score of 0-2;\n7. Hemoglobin ≥ 8.5 g\u002FdL Total bilirubin ≤ 30mmol\u002FL Serum albumin ≥ 32 g\u002FL ASL and AST ≤ 5 x upper limit of normal Serum creatinine ≤ 1.5 x upper limit of normal INR ≤ 1.5 or PT\u002FAPTT within normal limits Absolute neutrophil count (ANC) \\>1,500\u002Fmm3\n8. Prothrombin time ≤18s or international normalized ratio \\\u003C 1.7.\n9. Ability to understand the protocol and to agree to and sign a written informed consent document.\n\nExclusion Criteria:\n\n1. Diffuse HCC;\n2. Extrahepatic metastasis \\>5;\n3. Obstructive PVTT involving the main portal vein.\n4. Serious medical comorbidities.\n5. Evidence of hepatic decompensation including ascites, gastrointestinal bleeding or hepatic encephalopathy\n6. Known history of HIV\n7. History of organ allograft\n8. Known or suspected allergy to the investigational agents or any agent given in association with this trial.\n9. Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy\n10. Evidence of bleeding diathesis.\n11. Patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry.",{"count":114,"type":21},40,[116],"NA","This study intends to evaluate the efficacy and safety of blank- microsphere transcatheter arterial embolization-hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin (bTAE-HAIC) plus Lenvatinib and Camrelizumab for patients with intermediate-advanced huge hepatocellular carcinoma.",[119,120,121,29,122],"Liver Diseases","Hepatocellular Carcinoma","Immunotherapy","Lenvatinib","2024-09-20",{"date":125,"type":35},"2024-09-23",{"date":127,"type":35},"2024-05-20",{"date":129,"type":21},"2025-12-30",{"name":131,"class":42},"Sun Yat-sen University",{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":22,"phases":141,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":146,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":4},"100537369","phase-4-a-study-of-camrelizumab-combined-with-chemotherapy--thalidomide-in-first-line-treatment-of-patients-with-advanced-non-small-cell-lung-cancer-nsclc-100537369","NCT06276933","A Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)","A Prospective, Multicenter, Double-blind, Randomized Controlled Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced NSCLC","Inclusion Criteria:\n\n1. Age ≥18 years old, both male and female.\n2. Histopathology or cytology confirmed advanced Stage IIIB-IV non-small cell lung cancer.\n3. No prior systemic treatment to advanced NSCLC . Subjects who have received prior neo-adjuvant, adjuvant chemotherapy, or chemoradiotherapy with curative intent for non-metastatic disease must have experienced a treatment free interval of at least 12 months from randomization since the last chemotherapy cycle.\n4. Subjects must have measurable disease by CT or MRI per RECIST 1.1 criteria.\n5. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1.\n6. Have a life expectancy of at least 3 months.\n7. All baseline laboratory requirements will be assessed.\n8. Can swallow pills normally.\n9. Remission of all acute toxic reactions to previous antitumor therapy to grade 0-1 or to the level specified in the exclusion criteria.\n10. Female Subjects of childbearing potential must have a negative serum pregnancy test within 7 days before the first dose, are not breastfeeding, and must be willing to use very efficient barrier methods of contraception for the course of the study through 180 days after the last dose of study treatment. Male subjects whose partners are fertile women should be surgically sterilized or agree to use effective contraception during the trial period and 90 days after the last administration of the study drug, and sperm donation is not allowed during the study period.\n11. Subjects has voluntarily agreed to participate by giving written informed consent. Willing and able to follow planned visits, research treatments, laboratory tests and other test procedures.\n\nExclusion Criteria:\n\n1. Patients with non-small cell lung cancer diagnosed with other histopathological types, including patients with NSCLC containing small cell lung cancer components.\n2. Subjects with epidermal growth factor receptor (EGFR)-sensitizing mutation and\u002For anaplastic lymphoma kinase (ALK) translocation.\n3. Patients who have previously received PD-(L)1 or CTLA-4 treatment.\n4. Subjects with active CNS metastases are excluded.\n5. Subjects with active, known or suspected autoimmune disease. Participants who are in a stable state and do not require systemic immunosuppressive therapy are permitted to enroll.\n6. Congenital or acquired immunodeficiency, such as human immunodeficiency virus (HIV) infection.\n7. Have the following poorly controlled infectious diseases: active viral hepatitis B or C; Have active TB or are currently receiving anti-TB treatment.\n8. There is past or present objective evidence of idiopathic pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia, tissue pneumonia (such as bronchitis, vasculitis obliterans), drug-induced pneumonia, active pneumonia on CT examination, or severe impairment of lung function.\n9. Subjects with clinically significant cardiovascular and cerebrovascular diseases.\n10. Active infection (CTCAE\\> Grade 2).\n11. Diagnosed with immune deficiency or receiving systemic glucocorticoid therapy or any other form of immunosuppressive therapy not directly related to tumor treatment within 7 days prior to study enrollment; Physiological doses of glucocorticoids are permitted.\n12. Other malignancies developed within 5 years prior to admission, excluding adequately treatable cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical surgery, and ductal carcinoma in situ after radical surgery.\n13. Subjects received major surgery within 4 weeks of the first dose of study treatment or planned during the study period.\n14. Subjects had administration of a live, attenuated vaccine within 4 weeks of the first dose of study treatment or anticipation that such a live attenuated vaccine will be required during the study.\n15. Subjects who are alcohol dependent or have a history of drug or substance abuse within the last 1 year.\n16. Subjects with a known neurological or mental disorder, such as epilepsy, dementia, or the presence of a peripheral nervous system disorder.\n17. Subjects had or plan to have allogeneic bone marrow transplantation or solid organ transplant.\n18. Pregnant or lactating female; The fertile subject is unwilling or unable to take effective contraceptive measures.\n19. Known allergy to the investigational drug or excipient.\n20. Received any other investigational medicine treatment or participated in another interventional clinical study within 4 weeks prior to signing the ICF.\n21. Abnormal coagulation function .Thrombosis or thromboembolic event within 6 months prior to the start of study treatment.\n22. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject\\'s participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating Investigator.",{"count":140,"type":21},104,[142],"PHASE4","To explore and evaluate the safety and efficacy of camrelizumab combined with chemotherapy ± thalidomide in first-line treatment of advanced non-small cell lung cancer patients",[145,29],"Lung Cancer","NOT_YET_RECRUITING","2024-02-23",{"date":149,"type":35},"2024-02-26",{"date":151,"type":21},"2024-02-22",{"date":153,"type":21},"2026-11-22",{"name":155,"class":42},"Tongji University"]